Lupus & antiphospholipid syndrome
Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta‐Analysis
Pooled result · Clinical responseResult — go to the resultPooled odds ratio 1.44 95% CI 1.20–1.74Authors' conclusion
The findings support belimumab as an effective therapy for CLE with SLE.
Study context
- Population
- Patients with cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE)14 studies
- Comparison
- Belimumab users vs nonusers
- Outcome
- Clinical response
- Follow-up
- 52 weeks
Methodological detailsrandom-effects model, 747 screened studies, 14 included
- Random-effects model
- 747 screened studies, 14 included
Pooled result
As reported in the abstract
Pooled odds ratio
1.44
95% CI 1.20–1.74
Belimumab usersvs Nonusers
pooled OR 1.44 (95% CI 1.20–1.74)
Further pooled results
Time to first clinical response after starting belimumab (pooled OR per consecutive 4-week interval) · 20 weeks
- Clinical response first noted after 20 weeks of starting belimumab
- OR 1.35 [95% CI 1.01-1.81]
- Sustained clinical response through 1 year
- I2 = 0%
Original publication
Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta‐Analysis. Arthritis Care Res (Hoboken). Published 3 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →